Recent Major Announcements
TFA’s China licensee HuanZhang has entered Shanghai Pharma’s Antrodia camphorata raw-material supply chain and, as of September 18, 2026, was the program’s only qualified supplier, adding quality and supply-chain experience relevant to TFA-01 development in China.
Read the full releaseTFA completed a preliminary 14-day repeat-dose study of TF-15 in rats, with the summary report signed on July 2, 2026. The company is continuing safety, toxicology, and formulation research to support TFA-01.
Read the full release01 · Therapeutic Rationale & Scientific Evidence
Corticosteroids have well-established therapeutic value, but the challenges of repeated or prolonged use create demand for new treatments. TFA-01 is an Antcin A-based drug candidate being studied for its potential to provide anti-inflammatory activity with an improved long-term benefit-risk profile.
Preparing interactive model
This model uses a computed conformer from PubChem (NCBI/NLM/NIH), CID 10004121; CAS 163597-24-8, molecular formula C₂₉H₄₂O₄. The source record does not specify the stereochemistry at C25; this view shows one computed conformer. PubChem ↗
Chronic inflammatory conditions require ongoing management. TFA aims to develop a new treatment option and evaluate its potential for repeated use.
A 2011 cell study reported that Antcin A induced nuclear translocation of the glucocorticoid receptor (GR)—movement of the receptor from the cytoplasm into the nucleus.
Read the original studyPreliminary in vitro research by Dr. Huang’s team observed anti-inflammatory signals, supporting further work on dosing, formulation, safety, and canine OA.
GR nuclear translocation and in vitro findings support further development; potential as an alternative to corticosteroids requires validation in formal studies.
Explore the scientific evidenceFrom molecular insight to a drug development asset
Translating scientific findings into an investigational product requires coordinated work on dosing, formulation, safety, and clinical evidence. Canine OA is the lead indication, with other chronic inflammatory conditions to be evaluated over time.
02 · Initial Market & Lead Indication
Companion animal health is TFA’s initial commercial focus. Within that market, canine osteoarthritis (OA) is the starting point for research and product development.
Pet owners’ demand for pain relief and better quality of life supports an ongoing treatment market. A phased veterinary-drug development plan helps align research milestones with funding needs.
Canine OA requires long-term management, with pain and mobility providing measurable outcomes. Studies will evaluate efficacy, repeat-dose safety, and appropriate dosing and treatment duration.
Canine OA studies are intended to build the evidence base for the lead indication. Feline chronic gingivostomatitis and dermatitis will be evaluated separately in subsequent research.
03 · Development Progress
Building on scientific findings and exploratory data, five development workstreams are generating the evidence needed for formal studies, product quality, and regulatory submissions.
Published studies support GR/GRα-related signaling by Antcin A in defined models. TFA is assessing how those findings apply to its current test articles, batches and canine OA development program.
Next milestoneComplete candidate test-article and batch definition and strengthen program-level pharmacology relevant to canine osteoarthritis.View progress detailsResearch on strains from multiple sources and their Antcin A content supports controlled cultivation, strain selection, purification, analytical testing and formulation development.
Next milestoneComplete physicochemical validation of the nanoformulation, then advance formal specifications, batch consistency and process scale-up.View progress detailsA 14-day repeat-dose preliminary toxicology study in female rats is complete and a report is available to inform later study design. The Graduate Institute of Animal Vaccine Technology is advancing target-animal safety, toxicology, residue and formulation-related research.
Next milestoneComplete the subsequent regulatory toxicology reports and establish the safe dose range for the purified candidate drug substance and final product under this development program.View progress detailsTFA completed uncontrolled exploratory observations in 15 dogs. The first-stage canine osteoarthritis research agreement has been signed, and preliminary cell-based testing is underway ahead of a standardized study.
Next milestoneComplete the canine OA study under a protocol with prespecified endpoints and a statistical analysis plan, and prepare the study report.View progress detailsTFA is assembling data for a veterinary drug application in Taiwan and planning its U.S. CVM strategy. Partnership and licensing opportunities will be evaluated as the supporting data develop.
Next milestoneObtain regulatory feedback on study design, process specifications and remaining data gaps, then develop a submission plan.View progress details04 · Technology & Supply Capabilities
Developing a naturally occurring active compound requires a dependable source of research material. TFA combines HPF (Hyphal Pairing & Fusion), quantitative screening, and cultivation processes to establish that supply foundation.
Compatible hyphal pairings are established, then screened by quantitative analysis to select strains with high Antcin A yields for cultivation and scale-up.
Estimated Antcin A content equivalent in material from current Taiwan cultivation capacity, supporting multiple research batches, formulation development, and quality comparisons.
Relevant cultivation patents in Taiwan, China, Japan, and the United States complement strain selection and cultivation processes as part of TFA’s technology foundation.
TFA-HPF™ · Hyphal Pairing & Fusion
HPF provides strains for ongoing cultivation and research. It supports TFA’s supply capabilities alongside cultivation processes, quality analysis and downstream processing.
Establish compatible hyphal pairings as the starting point for strain development.
Actual culture-plate photo; numbers and animation illustrate hyphal pairing and fusion.
HPF and the cultivation patents in four jurisdictions are presented separately. The granted patent claims define the scope of protection.
The supply estimate represents Antcin A content equivalent within cultivated material. Purified API and final injectable-product output require separate process and quality validation.
Explore HPF and supply capabilities05 · Commercialization & Company Value
As research and regulatory work advance, TFA plans to pursue commercialization through product sales, regional licensing, and co-development across markets.
Build on the lead product program and veterinary distribution channels to launch sales after obtaining the required approvals.
Work with regional partners on regulatory submissions and commercialization, with potential licensing fees, milestone payments, or royalties under the relevant agreements.
Combine partners’ research, regulatory, and market capabilities to share development responsibilities and the resulting value.
TFA CORPORATE FILM
An introduction to the scientific basis for Antcin A, TFA-01’s five development workstreams and the company’s public-market reporting framework.
LEADERSHIP
Two co-founders directly lead corporate management and technology development.
Meet our leadershipLATEST UPDATES
INVESTOR RELATIONS
TFA Therapeutics, Inc. is an SEC-reporting foreign private issuer quoted on OTCQB as RAJAF.
We welcome animal-health, pharmaceutical, clinical, CMC, regulatory and long-term investment partners.
Contact TFA